Dividend stocks boomed from early July 2024 to late November 2024. However, since then, they have pulled back sharply. I discuss the bad news that may continue weighing on many dividend stocks.
Alexandria Real Estate Equities offers a 5.3% yield, making it an attractive long-term investment despite recent share price declines and a challenging market. ARE's financials remain strong with solid AFFO and revenue growth, and management has confidence in the stock's undervaluation and future upside. The REIT's balance sheet is robust, with low net debt to EBITDA and significant liquidity, positioning it well against peers like Healthpeak Properties and Omega Healthcare Investors.
Alexandria Real Estate's bull thesis was flawed. FFO estimates for ARE have dropped 20% over the last 18 months. The key bear fodder came from the REIT's 2025 guidance.
Falling interest rates and Trump's policies could boost demand, making REITs with strong balance sheets and attractive valuations poised for significant returns. Alexandria Real Estate, a life science REIT, offers stable cash flows, high occupancy, and a strong balance sheet, despite recent underperformance. Rexford Industrial, focused on Southern California, boasts diversified tenants and impressive growth, though faces risks from geographic concentration and potential tariff impacts.
Kevin Maloney, founder and CEO at PMG, joins CNBC's ‘The Exchange' to discuss his 2025 commercial real estate outlooks, top real estate trends to watch, and more.
REITs have strongly recovered. As a result, some have become overvalued. I highlight 3 REITs to sell before 2025.
Going into 2024, the consensus was that REITs would surge higher. While the base rates have dropped, the REIT investment case has failed. Yet, as long as the objective is to extract durable income, I would argue that now is the right time to make huge moves in the REIT segment.
ARE is a leading REIT in life science properties, facing challenges due to a downturn in the life science market. ARE's shares have dropped 55% from their peak but continue to grow FFO per share. ARE's strategic moves include a $500 million share repurchase plan.
Alexandria RE is significantly undervalued compared to other U.S. equities, presenting a buy opportunity for contrarian investors. Historical performance during the Dotcom technology bust period suggests ARE could see robust gains years into the future, from countertrend capital flows toward value and income ideas. ARE's balance sheet is strong with low fixed-rate debt and operations stable with mostly pharmaceutical tenants, making it a safer investment amid potential market volatility.
Ahead of the Federal Reserve's critical interest rate decision next week, U.S. equity markets snapped a three-week winning streak as benchmark interest rates jumped to the cusp of five-month highs. Lukewarm CPI and PPI inflation reports were "good enough" to solidify another Fed rate cut next week, but "sticky" trends called into question the outlook for continued easing in 2025. After setting a series of fresh record-highs in the prior week, the S&P 500 slipped 0.6% this week, but still remains on pace for its best year since 2019.
Alexandria's dividend hike of 1.5% and $500 million stock buyback plan boost investors' confidence in the stock.
Corporations often increase dividend payouts in Q1 of each year, making it crucial for income investors to position portfolios for 2025. Dividend growth investing is appealing due to recent federal funds rate cuts, offering multiple benefits like capital appreciation, inflation hedging, and compounding returns. Companies like Canadian Natural Resources, Brookfield Renewable Partners, Alexandria Real Estate Equities, and Prologis are well-positioned for dividend hikes due to strong cash flows and sustainable business models.